Moderna and Merck announce ‘landmark’ trial showing mRNA therapy significantly cuts odds of recurrent skin cancer
The combined drug works by nudging the body’s own immune system to make proteins that attack and destroy melanoma cells
We haven't written up this one. Scientific American has the full story — the link below goes straight to it.